Advanced melanoma

Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In...


Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage...


Treatment with programmed death receptor-1 ( PD-1 ) antibodies is associated with high response rates in patients with advanced melanoma....


Epacadostat is an oral, potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 ( IDO1 ), a tryptophan-catabolizing enzyme that induces immune...


The advent of new immunotherapies for the treatment of metastatic melanoma has resulted in various novel combination strategies. Because of...


With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a...


The European Commission ( EC ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 therapy, at a dose of 2...


The FDA ( Food and Drug Administration ) has expanded the approved use of Opdivo ( Nivolumab ) to treat...


Nivolumab ( Opdivo ) was associated with higher rates of objective response than chemotherapy in a phase 3 study involving...


The FDA ( Food and Drug Administration ) has granted Priority Review for the New Drug Application ( NDA )...


The FDA ( Food and Drug Administration ) has granted accelerated approval for Keytruda ( Pembrolizumab ) to treat patients...


The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) to treat patients with advanced (...


Adoptive cell therapy ( ACT ) for cancers using autologous tumor-infiltrating lymphocytes ( TILs ) can induce immune responses and...


The results of the pivotal OPTiM study have shown that Talimogene laherparepvec monotherapy is the first oncolytic immunotherapy to demonstrate...


The Food and Drug Administration ( FDA ) has approved Duopa ( Carbidopa and Levodopa ) enteral suspension for the...


Findings investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell...


Keytruda ( Pembrolizumab ) is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over...